

**Department of Planning and Budget**  
**2026 General Assembly Session**  
**State Fiscal Impact Statement**

---

**PUBLISHED: 2/26/2026 12:47 PM**

**ORIGINAL**

**Bill Number:** SB379 ER

**Patron:** Boysko

**Bill Title:** Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes.

**Bill Summary:** Directs the Board of Pharmacy to reschedule an FDA-approved formulation of psilocybin designed to be administered by a health care professional in a health care setting at its next quarterly meeting, following the expiration of 30 days from publication in the Federal Register of a final or interim final order or rule that designates any formulation of FDA-approved psilocybin as a controlled substance.

**Budget Amendment Necessary:** No

**Items Impacted:** n/a

**Fiscal Summary:** Minimal/absorbable fiscal impact.

**Fiscal Analysis:** This legislation requires the Board of Pharmacy (the Board) to reschedule a formulation of psilocybin that is designed to be administered by a health care professional in a health care setting upon approval of a formulation by the U.S. Food and Drug Administration (FDA). The Board is directed to reschedule such formulation at its next quarterly meeting following the expiration of 30 days from publication in the Federal Register of a final or interim final order or rule that designates any formulation of FDA-approved psilocybin as a controlled substance. It is expected that any cost or workload impacts to the Board of Pharmacy associated with the rescheduling process will be minimal and absorbable within existing resources.

**Other:** SB379 may be a companion to HB1347.